Robert Curtis
LogicMarkAbout Robert Curtis
Robert Curtis, age 70, has served as an independent director of LogicMark, Inc. since July 25, 2018, and currently chairs the Compensation Committee while also serving on the Audit and Corporate Governance & Nomination Committees -. He is a 36-year biosciences industry veteran and consultant (Curtis Consulting & Communications, LLC) with prior CEO/founding roles at multiple life sciences and technology ventures; he holds a BS in Pharmacy (Massachusetts College of Pharmacy), a Pharm.D. (University of Missouri), and an MBA (Columbia University) .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Curtis Consulting & Communications, LLC | Consultant to emerging technology companies | Since 2012 | Advises early-stage tech firms |
| Trudeau Institute (Saranac Lake, NY) | Executive Chairman and Director | 2014–2016 | Leadership of research institute |
| Regional Technology Development Corporation (Woods Hole, MA) | Chief Executive Officer | 2007–2012 | Commercialization of Marine Biological Laboratory and WHOI technologies |
| HistoRx, Inc. | Founder and CEO | Not disclosed | Tissue proteomics; commercialization leadership |
| Cape Aquaculture Technologies, Inc. | Founder and CEO | Not disclosed | Developed enhanced non-GMO fish |
| Lion Pharmaceuticals / Phoenix Drug Discovery LLC | Founder and CEO | Not disclosed | University-based drug discovery commercialization |
| Environmental Operating Solutions, Inc. | Assisted founding; company sold in 2017 | Not disclosed | Applied denitrification technology to wastewater |
| CombiChem, Inc. | Co-founder and CEO | Not disclosed | Company sold to DuPont Pharmaceuticals |
| MetaMorphix, Inc. (JV Genetics Institute & Johns Hopkins) | Founding President and CEO | Not disclosed | JV in biotech; executive leadership |
| Pharmacopeia, Inc.; Cambridge Neuroscience, Inc.; Pfizer, Inc. | Senior management roles | Not disclosed | Pharma/biotech operations |
| University of Illinois Medical Center (Chicago) | Assistant Professor of Pharmacy Practice | Not disclosed | Academic appointment |
External Roles
| Organization | Role | Nature | Notes |
|---|---|---|---|
| Private entrepreneurial companies | Board member or advisor | Private | Multiple private company boards/advisory roles (names not disclosed) |
| Falmouth Commodores (Cape Cod Baseball League) | President | Non-profit/Sports | Governance and executive committee leadership |
| Cape Cod Baseball League | Executive Committee member | Non-profit/Sports | League oversight |
| MIT $100K Business Plan Competition | Judge | Academic/Entrepreneurship | External innovation ecosystem involvement |
Board Governance
- Independence: The Board determined Robert Curtis is independent under Nasdaq rules (Rule 5605(a)(2)) .
- Committee assignments:
- Compensation Committee: Chair -
- Audit Committee: Member (committee chaired by Barbara Gutierrez; she is Audit Committee Financial Expert) -
- Corporate Governance & Nomination Committee: Member (chaired by John Pettitt)
- Attendance: In FY2024, the Board met six times; except for one absence by John Pettitt, no director attended fewer than 100%—implying Curtis attended all Board meetings . Audit Committee held four meetings with all members present; Compensation Committee held one meeting with all members present; Corporate Governance & Nomination Committee did not meet in 2024 -.
- Annual meeting attendance: All then-sitting directors except Carine Schneider and Barbara Gutierrez attended the 2024 Annual Meeting—implying Curtis attended .
- Years on board: Director since July 25, 2018 .
- Leadership structure: Chair of the Board and lead independent director role held by Carine Schneider (Curtis is not LID) .
Fixed Compensation
Director compensation for FY2024 (paid quarterly) :
| Metric | FY 2024 |
|---|---|
| Fees Earned (Cash) | $63,000 |
| Stock Awards | — |
| Stock Option Awards (grant-date fair value) | $49,726 |
| Non-Equity Incentive Comp | — |
| Nonqualified Deferred Comp Earnings | — |
| All Other Compensation (Primarily travel reimbursements) | $6,364 |
| Total | $119,090 |
| Option Strike (avg for director grants) | ~$11.66 per share (average) |
Notes:
- Non-employee directors received cash retainers and stock options; options were granted with an average exercise price of approximately $11.66 per share .
Other Directorships & Interlocks
| Category | Details |
|---|---|
| Current public company boards | None disclosed in biography |
| Private company/non-profit boards | Board/advisor to multiple private entrepreneurial companies; President of Falmouth Commodores; Cape Cod Baseball League Executive Committee |
| Family relationships | None disclosed among directors/officers |
| Related-party transactions | None involving directors/officers other than described; no transactions reported with Curtis |
Expertise & Qualifications
- 36-year biosciences operator and founder with commercialization experience across diagnostics, aquaculture, and drug discovery (HistoRx, CombiChem, Lion/ Phoenix Drug Discovery, MetaMorphix) .
- Governance and comp experience: Chairs Compensation Committee; committee oversees CEO goals/bonus structure and director compensation; qualified as “non-employee director” for Rule 16b-3 -.
- Education: BS (Pharmacy), Pharm.D., MBA (Columbia University) .
- Not designated audit committee financial expert; ACFE designation held by Barbara Gutierrez .
Equity Ownership
As of July 9, 2025 (beneficial ownership basis) -:
| Holding Detail | Amount | Terms |
|---|---|---|
| Common shares owned | 876 | |
| Stock options (exercisable) | 3,011,307 | Weighted avg exercise price ~$0.08 per share |
| Warrants (Series A & B) | 90,452 | Weighted exercise price ~$0.22 per share (Aug 2024 offering) |
| Total beneficially owned (incl. exercisable within 60 days) | 3,102,635 | |
| Percent of total voting power | Less than 1% | |
| Shares outstanding context | 576,305,099 Common; 1 Series C Preferred; 106,333 Series F Preferred (as-converted 107 Common) |
Policy context:
- Hedging transactions are prohibited for directors under the insider trading policy; pledging is not specifically addressed in the disclosed excerpt (no pledging by Curtis disclosed) .
Governance Assessment
-
Strengths
- Independent status with full Board and committee attendance in 2024; chairs Compensation Committee and serves on Audit and Governance committees, evidencing broad governance engagement -.
- Relevant operating experience across healthcare/biotech and commercialization, adding complementary expertise to a technology-enabled safety/monitoring business .
- No disclosed legal proceedings, family relationships, or related-party transactions tied to Curtis; Audit Committee oversight explicitly includes related-party review - .
-
Areas to monitor
- Compensation Committee met once in 2024; while all members attended, low meeting frequency warrants monitoring given the company’s evolving capital structure and incentive plan administration needs .
- Company-level capital actions (reverse stock splits; OTC quotation following Nasdaq delisting) elevate broader governance/compensation scrutiny, though these are company-wide issues and not specific to Curtis; the Board cites liquidity/uplisting objectives for these actions -.
-
RED FLAGS observed specific to Curtis
- None disclosed: no attendance lapses, no related-party ties, no adverse legal history, and compliance with independence standards - .